
<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Drug Discovery Pipeline Knowledge Base</title>
  <link rel="stylesheet" href="styles.css" />
</head>
<body>
  <header>
    <h1>Drug Discovery Pipeline Knowledge Base</h1>
    <p>Comprehensive guide to the stages of drug development</p>
  </header>
  <nav>
    <ul>
      <li><a href="target_identification.html">Target Identification</a></li>
      <li><a href="hit_discovery.html">Hit Discovery</a></li>
      <li><a href="lead_optimization.html">Lead Optimization</a></li>
      <li><a href="preclinical.html">Preclinical Development</a></li>
      <li><a href="clinical.html">Clinical Trials</a></li>
      <li><a href="regulatory.html">Regulatory Approval</a></li>
      <li><a href="post_marketing.html">Post-Marketing Surveillance</a></li>
    </ul>
  </nav>

  <main>
    <section>

<h2>Druggability: Structural and Translational Perspectives</h2>

  <div class="section">
    <h2>1. What Is Druggability?</h2>
    <p>Druggability refers to the potential of a biological target to be modulated by a drug-like molecule in a way that produces a therapeutic effect. It encompasses structural compatibility, functional relevance, and clinical feasibility.</p>
  </div>

  <div class="section">
    <h2>2. Structural Features</h2>
    <ul>
      <li><strong>Binding Pocket Characteristics:</strong> Size, shape, depth, and hydrophobicity influence ligand compatibility.</li>
      <li><strong>Allosteric Sites:</strong> Enable selective modulation beyond conserved active sites.</li>
      <li><strong>Cryptic Sites:</strong> Transient pockets revealed through conformational dynamics or fragment binding.</li>
    </ul>
  </div>

  <div class="section">
    <h2>3. Biophysical and Biochemical Properties</h2>
    <ul>
      <li><strong>Ligand Efficiency Metrics:</strong> LE, LLE, and FQ assess binding quality relative to molecular size and lipophilicity.</li>
      <li><strong>Target Flexibility:</strong> Dynamic proteins may require stabilization of specific conformers.</li>
      <li><strong>Surface Accessibility:</strong> Determines feasibility of targeting membrane-bound or intracellular proteins.</li>
    </ul>
  </div>

  <div class="section">
    <h2>4. Biological Relevance</h2>
    <ul>
      <li><strong>Functional Modulation:</strong> Binding must alter activity meaningfully (inhibition, activation, degradation).</li>
      <li><strong>Pathway Integration:</strong> Target should influence disease-relevant signaling cascades.</li>
      <li><strong>Tissue Selectivity:</strong> Preferential expression in diseased tissue reduces off-target effects.</li>
    </ul>
  </div>

  <div class="section">
    <h2>5. Assessing Druggability</h2>
    <table>
      <thead>
        <tr>
          <th>Method</th>
          <th>Purpose</th>
          <th>Example</th>
        </tr>
      </thead>
      <tbody>
        <tr>
          <td>X-ray / cryo-EM</td>
          <td>Visualize pocket architecture</td>
          <td>Kinase inhibitor binding modes</td>
        </tr>
        <tr>
          <td>Fragment Screening</td>
          <td>Identify weak-binding fragments</td>
          <td>Cryptic sites in bromodomains</td>
        </tr>
        <tr>
          <td>Molecular Dynamics</td>
          <td>Explore pocket flexibility</td>
          <td>Allosteric sites in GPCRs</td>
        </tr>
        <tr>
          <td>Computational Scoring</td>
          <td>Quantify druggability (e.g., SiteMap)</td>
          <td>Virtual screening prioritization</td>
        </tr>
        <tr>
          <td>AI Prediction Models</td>
          <td>Integrate structure + omics</td>
          <td>Rare disease target discovery</td>
        </tr>
      </tbody>
    </table>
  </div>

  <div class="section">
    <h2>6. Expanding Druggability</h2>
    <ul>
      <li><strong>Proteinâ€“Protein Interactions:</strong> Targeted via hot spot mapping, stapled peptides, and molecular glues.</li>
      <li><strong>RNA Targets:</strong> Structured motifs (e.g., hairpins) enable small molecule or oligonucleotide targeting.</li>
      <li><strong>Targeted Protein Degradation:</strong> PROTACs and molecular glues expand druggability beyond inhibition.</li>
    </ul>
  </div>

  <div class="section">
    <h2>7. Strategic Implications</h2>
    <ul>
      <li><strong>Target Prioritization:</strong> Druggability scores guide early-stage decisions.</li>
      <li><strong>Modality Selection:</strong> Informs choice between small molecules, biologics, or nucleic acid therapies.</li>
      <li><strong>Risk Assessment:</strong> Low druggability may require novel chemistry or alternative modalities.</li>
    </ul>
  </div>



    </section>
  </main>
  <footer>
    <p>&copy; 2025 Drug Discovery Knowledge Base</p>
  </footer>
</body>
</html>
